NIHR Clinical Research Facility

London, United Kingdom

NIHR Clinical Research Facility

London, United Kingdom
SEARCH FILTERS
Time filter
Source Type

Davidson J.,University of Dundee | McDonald T.,NIHR Clinical Research Facility | Sutherland C.,University of Dundee | Mostazir M.,University of Exeter | And 2 more authors.
PLoS ONE | Year: 2017

Aims: Reference laboratories advise immediate separation and freezing of samples for the assay of proinsulin, which limit its practicability for smaller centres. Following the demonstration that insulin and C-peptide are stable in EDTA at room temperature for at least 24 hours, we undertook simple stability studies to establish whether the same might apply to proinsulin. Methods: Venous blood samples were drawn from six adult women, some fasting, some not, aliquoted and assayed immediately and after storage at either 4°C or ambient temperature for periods from 2h to 24h. Results: There was no significant variation or difference with storage time or storage condition in either individual or group analysis. Conclusion: Proinsulin appears to be stable at room temperature in EDTA for at least 24h. Immediate separation and storage on ice of samples for proinsulin assay is not necessary, which will simplify sample transport, particularly for multicentre trials. © 2017 Davidson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


News Article | November 18, 2016
Site: www.eurekalert.org

In a second boost for Manchester in as many months, a single city-wide bid has been awarded £12.5m by the Department of Health to fund the cutting-edge research space, highly trained staff and specialist equipment required to develop and deliver pioneering new treatments across three NHS sites in Greater Manchester. This new award is a major achievement for Greater Manchester Devolution, demonstrating synergy that can only be achieved by bringing together clinical and research expertise from across health and academia to deliver patient-orientated commercial and academic clinical research studies. It will enable expansion of existing clinical research capacity across Manchester and is hosted by Central Manchester University Hospitals NHS Foundation Trust (CMFT) in partnership with The Christie NHS Foundation Trust (The Christie), University Hospital of South Manchester NHS Foundation Trust (UHSM) and The University of Manchester. Clinical Research Facilities (CRF) at CMFT, The Christie and UHSM, currently facilitate a total of 6500 visits per year from patients and healthy volunteers involved in research studies. They provide 24-hour, seven-day inpatient and outpatient research services, including those for children and infants, with over 50 research beds and 20 outpatient consultation rooms across Greater Manchester. Manchester's unique proposal will make research more accessible to people of all ages and backgrounds across the city region, as well as expanding the volume and types of research undertaken. In September, the Department of Health announced a £28.5m investment in Manchester under its Biomedical Research Centre (BRC) scheme, which recognises Manchester's international reputation and will drive forward research in the areas of musculoskeletal disease, hearing health, respiratory disease, dermatology and three cancer themes (prevention, radiotherapy and precision medicine). This latest investment is provided under the NIHR Clinical Research Facility Scheme and will enable the Manchester CRFs to support researchers working in these areas and many others, representing major causes of premature death and disability for patients in Manchester and beyond. The Manchester CRFs are supported by the Manchester Academic Health Science Centre (MAHSC). Lord Peter Smith, Chair of Greater Manchester Health and Social Care Partnership Board said: "This reinforces Manchester's strong credentials in experimental medicine. The CRFs will play a key role in working with patients, academic and commercial research partners to implement the Greater Manchester Health and Social Care Devolution." Professor Nick Webb, Director of the Manchester CRF explained: "Our new One Manchester approach consolidates assets across our CRFs and will explore novel ways to drive efficiencies and maximise the impact of our research across Greater Manchester. "We know that disease burden remains disproportionately high in Manchester and especially in socially disadvantaged groups. Working with the BRC and NHS organisations across Manchester, our focus will be to increase accessibility of research for people of all ages and backgrounds right across the city region and beyond." Sir Michael Deegan, Chief Executive at CMFT said: "Experimental medicine studies can be extremely complex and intensive, requiring specialist facilities. This investment will enable us to expand our world-leading research in this area and provide more patients in Manchester with the opportunity to trial new medicines." Professor Dame Nancy Rothwell, President & Vice-Chancellor at The University of Manchester, added: "We're delighted to receive this investment, which recognises the excellent research infrastructure we already have in Manchester and will help to further accelerate the translation of basic laboratory research through to treatments that benefit patients." Minister for Public Health and Innovation Nicola Blackwood said: "Our investment in this area so far has led to a variety of breakthroughs, including the first new asthma treatment in a decade, and a promising treatment for peanut allergies in children, to name just two. "We know that such ground breaking clinical research simply would not happen without the support of these Clinical Research Facilities. "I'm delighted to announce this funding to support the skilled personnel and cutting-edge facilities we need to keep Manchester at the forefront of clinical research."


Crosby-Nwaobi R.,NIHR Clinical Research Facility | Hykin P.,NIHR Clinical Research Facility | Peto T.,NIHR Clinical Research Facility | Sivaprasad S.,NIHR Clinical Research Facility
Clinical Ophthalmology | Year: 2016

Purpose: The aim of this study was to assess the impact of daily oral supplementation with Macushield (10 mg/d meso-zeaxanthin, 10 mg/d lutein, and 2 mg/d zeaxanthin) on eye health in patients with retinal diseases by assessing the macular pigment (MP) profile, the visual function, and the quality of life. Methods: Fifty-one patients with various retinal diseases were supplemented daily and followed up for 6 months. The MP optical density was measured using the customized heterochromatic flicker photometry and dual-wavelength autofluorescence. Visual function was evaluated by assessing the change in best corrected visual acuity, contrast sensitivity, and glare sensitivity in mesopic and photopic conditions. Vision-related and general quality of life changes were determined using the National Eye Insititute- Visual Function Questionnaire-25 (NEI-VFQ-25) and EuroQoL-5 dimension questionnaires. Results: A statistically significant increase in the MP optical density was observed using the dual-wavelength autofluorescence (P=0.04) but not with the customized heterochromatic flicker photometry. Statistically significant (P<0.05) improvements in glare sensitivity in low and medium spatial frequencies were observed at 3 months and 6 months. Ceiling effects confounded other visual function tests and quality of life changes. Conclusion: Supplementation with the three carotenoids enhances certain aspects of visual performance in retinal diseases. © 2016 Crosby-Nwaobi et al.


PubMed | NIHR Clinical Research Facility
Type: | Journal: Clinical ophthalmology (Auckland, N.Z.) | Year: 2016

The aim of this study was to assess the impact of daily oral supplementation with Macushield (10 mg/d meso-zeaxanthin, 10 mg/d lutein, and 2 mg/d zeaxanthin) on eye health in patients with retinal diseases by assessing the macular pigment (MP) profile, the visual function, and the quality of life.Fifty-one patients with various retinal diseases were supplemented daily and followed up for 6 months. The MP optical density was measured using the customized heterochromatic flicker photometry and dual-wavelength autofluorescence. Visual function was evaluated by assessing the change in best corrected visual acuity, contrast sensitivity, and glare sensitivity in mesopic and photopic conditions. Vision-related and general quality of life changes were determined using the National Eye Insititute- Visual Function Questionnaire-25 (NEI-VFQ-25) and EuroQoL-5 dimension questionnaires.A statistically significant increase in the MP optical density was observed using the dual-wavelength autofluorescence (P=0.04) but not with the customized heterochromatic flicker photometry. Statistically significant (P<0.05) improvements in glare sensitivity in low and medium spatial frequencies were observed at 3 months and 6 months. Ceiling effects confounded other visual function tests and quality of life changes.Supplementation with the three carotenoids enhances certain aspects of visual performance in retinal diseases.

Loading NIHR Clinical Research Facility collaborators
Loading NIHR Clinical Research Facility collaborators